69000-93-7

Basic information

• Product Name: 1-(2-chloroethyl)-3-[3-(4-hexyl-2,3-dioxopiperazin-1-yl)propyl]-1-nitrosourea
• Synonyms: Urea, N-(2-chloroethyl)-N'-[3-(4-hexyl-2,3-dioxo-1-piperazinyl)propyl]-N-nitroso-
• CAS NO: 69000-93-7
• Molecular Formula: C₁₆H₂₈ClN₅O₄
• Molecular Weight: 389.8776
• Mol File: 69000-93-7.mol
• Article Data: 1

Chemical Properties

• Density: 1.29g/cm³
• Refractive Index: 1.575
• CAS DataBase Reference: 1-(2-chloroethyl)-3-[3-(4-hexyl-2,3-dioxopiperazin-1-yl)propyl]-1-nitrosourea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloroethyl)-3-[3-(4-hexyl-2,3-dioxopiperazin-1-yl)propyl]-1-nitrosourea(69000-93-7)
• EPA Substance Registry System: 1-(2-chloroethyl)-3-[3-(4-hexyl-2,3-dioxopiperazin-1-yl)propyl]-1-nitrosourea(69000-93-7)

Safety Data

• Hazardous Substances Data: 69000-93-7(Hazardous Substances Data)

Usage

Description

1-(2-chloroethyl)-3-[3-(4-hexyl-2,3-dioxopiperazin-1-yl)propyl]-1-nitrosourea, commonly known as BCNU, is a nitrosourea derivative used as an alkylating agent in chemotherapy. It is characterized by its ability to cross the blood-brain barrier, making it particularly effective against brain tumors. BCNU works by causing DNA damage in cancer cells, which leads to cell death. However, it has a narrow therapeutic window and can result in severe side effects such as myelosuppression and lung toxicity.

Uses

Used in Anticancer Applications:
BCNU is employed as an anticancer agent, specifically for the treatment of brain tumors, multiple myeloma, and Hodgkin's lymphoma. It modulates various cellular processes to exert its cytotoxic effects on cancer cells, leading to their death. Due to its ability to cross the blood-brain barrier, BCNU is particularly effective in treating brain tumors.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, BCNU is used as a key component in the development of chemotherapy regimens for various types of cancer. Its unique properties, such as the ability to cross the blood-brain barrier, make it a valuable asset in the fight against cancer.
Used in Drug Delivery Systems:
To overcome the limitations of BCNU, such as its narrow therapeutic window and potential for severe side effects, researchers are developing novel drug delivery systems. These systems aim to improve the delivery, bioavailability, and therapeutic outcomes of BCNU by employing various organic and metallic nanoparticles as carriers. This approach can potentially enhance the efficacy of BCNU while minimizing its side effects.

Relevant articles and documents

Synthesis and physico-chemical properties of 1-(2-chloroethyl)-3-(4-substituted- 2,3-dioxo-1-piperazinylalkyl)-1-nitrosourea

-